A Sermorelin trial dose isn’t a personal prescription
A dose copied from a paper can look like a ready-made answer. The missing details are who received it, why, and how it was given. Here are the research choices behind a few familiar numbers. They describe studies, not a schedule to follow.

1992
An adult experiment
The 1992 trial tested two doses
In the 1992 Corpas trial, participants were healthy older men who received 0.5 mg or 1 mg of Sermorelin twice daily for fourteen days. Researchers measured growth hormone and IGF-1, a growth factor that responds to growth hormone. This was a short experiment in hormone responses.
At the higher trial dose, those measurements no longer differed from the younger comparison group’s. That doesn’t establish a routine adult wellness dose. The researchers were answering a specific question in a small group, rather than writing directions for everyone who later searched the medicine’s name.
1993
The way it was given
A nasal dose isn’t an injection dose
The 1993 Wilton study tested Sermorelin given into a vein or through the nose in healthy men. Only a small fraction of the nasal dose reached the bloodstream. This study didn’t test an injection under the skin, a swallowed product or a form held under the tongue.
It doesn’t provide a conversion between those forms. The amount used and the amount absorbed aren’t the same thing. That’s why changing the route is a much bigger step than swapping one number for another. This finding explains a research limit, rather than offering a way to calculate a personal dose.
1996
A children’s trial
The pediatric dose answered a growth question
In the 1996 Thorner trial, researchers gave participants 30 micrograms per kilogram of body weight per day as an injection under the skin at bedtime. The participants were children before puberty with growth hormone deficiency. The aim was to study height growth.
Growth sped up during the first year, but the study had no untreated comparison group. Moving its dose into an adult wellness plan would change both the people and the goal. The children’s history explains the finding in its original setting.
What belongs in a prescription conversation?
What is treatment meant to help? What evidence supports that use? How will the prescriber decide whether it’s helping? Those questions are more useful than trying to make an old trial number fit a new person.
Compounded Sermorelin is not FDA-approved. Earlier research also reported flushing and injection-site pain, and prolonged adult safety remains uncertain. Questions about an existing prescription’s concentration or directions belong with the prescriber and dispensing pharmacy, who can identify the preparation involved. This guide gives no mixing, storage or injection instructions.